Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis
Daifuku, R.; Panacek, E.A.; Haenftling, K.; Swenson, W.K.; Prescott, A.W.; Johnson, J.L.
Human Antibodies and Hybridomas 4(1): 36-39
1993
ISSN/ISBN: 0956-960X PMID: 8431557 Document Number: 419754
MAB-T88 is a human monoclonal IgG antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.